PUNE, India, April 7, 2017 /PRNewswire/ --
ReportsnReports.com adds "Duchenne Muscular Dystrophy - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Browse 65 market data tables and 11 figures; spread across 275 pages is available at http://www.reportsnreports.com/reports/928823-duchenne-muscular-dystrophy-pipeline-review-h1-2017.html
Companies discussed in this Duchenne Muscular Dystrophy Pipeline Review, H1 2017 report include Acceleron Pharma Inc, Akashi Therapeutics Inc, Asklepios BioPharmaceutical Inc, BioMarin Pharmaceutical Inc, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Cardero Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Daiichi Sankyo Company Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Ltd, FibroGen Inc, Galapagos NV, Genethon SA, GTx Inc, GW Pharmaceuticals Plc, Idera Pharmaceuticals Inc, Italfarmaco SpA, La Jolla Pharmaceutical Company, Lexicon Pharmaceuticals Inc, Marina Biotech Inc, Merck KGaA, Milo Biotechnology LLC, Mitobridge Inc, Mitochon Pharmaceuticals Inc, MyoTherix Inc, NicOx SA, Nippon Shinyaku Co Ltd, Nobelpharma Co Ltd, Novartis AG, Pfizer Inc, Pluristem Therapeutics Inc, Prothelia Inc, PTC Therapeutics Inc, RASRx LLC, ReveraGen BioPharma Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd and WAVE Life Sciences Ltd.
Order a Purchase Copy of this Report @ http://www.reportsnreports.com/purchase.aspx?name=928823.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 7, 2, 51, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Infectious Disease). The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Duchenne Muscular Dystrophy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Infectious Disease).
This guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Related Reports:
Alzheimer's Disease - Pipeline Review, H1 2017
Meniere Disease - Pipeline Review, H1 2017
Liver Cirrhosis - Pipeline Review, H1 2017
Explore more reports on Pharmaceuticals Market http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari 2nd Floor, Metropole Building, Next to Inox Theatre, Bund Garden Road, Pune - 411013. Maharashtra, India. +1-888-391-5441 [email protected]
Connect with Us: LinkedIn: http://www.linkedin.com/company/reportsnreports RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
SOURCE ReportsnReports
Advertisement
ReportsnReports.com adds "Duchenne Muscular Dystrophy - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Advertisement
Browse 65 market data tables and 11 figures; spread across 275 pages is available at http://www.reportsnreports.com/reports/928823-duchenne-muscular-dystrophy-pipeline-review-h1-2017.html
Companies discussed in this Duchenne Muscular Dystrophy Pipeline Review, H1 2017 report include Acceleron Pharma Inc, Akashi Therapeutics Inc, Asklepios BioPharmaceutical Inc, BioMarin Pharmaceutical Inc, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Cardero Therapeutics Inc, Catabasis Pharmaceuticals Inc, CRISPR Therapeutics, Daiichi Sankyo Company Ltd, Debiopharm International SA, Editas Medicine Inc, Eloxx Pharmaceuticals Ltd, FibroGen Inc, Galapagos NV, Genethon SA, GTx Inc, GW Pharmaceuticals Plc, Idera Pharmaceuticals Inc, Italfarmaco SpA, La Jolla Pharmaceutical Company, Lexicon Pharmaceuticals Inc, Marina Biotech Inc, Merck KGaA, Milo Biotechnology LLC, Mitobridge Inc, Mitochon Pharmaceuticals Inc, MyoTherix Inc, NicOx SA, Nippon Shinyaku Co Ltd, Nobelpharma Co Ltd, Novartis AG, Pfizer Inc, Pluristem Therapeutics Inc, Prothelia Inc, PTC Therapeutics Inc, RASRx LLC, ReveraGen BioPharma Inc, Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Strykagen Corp, Summit Therapeutics Plc, Taiho Pharmaceutical Co Ltd and WAVE Life Sciences Ltd.
Order a Purchase Copy of this Report @ http://www.reportsnreports.com/purchase.aspx?name=928823.
The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 7, 2, 51, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 8 and 1 molecules, respectively.
Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Infectious Disease). The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Duchenne Muscular Dystrophy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Infectious Disease).
This guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Related Reports:
Alzheimer's Disease - Pipeline Review, H1 2017
Meniere Disease - Pipeline Review, H1 2017
Liver Cirrhosis - Pipeline Review, H1 2017
Explore more reports on Pharmaceuticals Market http://www.reportsnreports.com/market-research/pharmaceuticals/.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari 2nd Floor, Metropole Building, Next to Inox Theatre, Bund Garden Road, Pune - 411013. Maharashtra, India. +1-888-391-5441 [email protected]
Connect with Us: LinkedIn: http://www.linkedin.com/company/reportsnreports RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
SOURCE ReportsnReports
